ArticleJournal of hematology & oncology2021

HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast.

Ivan Bièche et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.